---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-24-000125"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:02:49.254620+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q1 revenue $5.6M (+11% YoY), loss $13.3M; reaffirms FY guidance

## Summary
- Q1 revenue $5.6M (+11% YoY); net loss $13.3M ($0.31/share).
- Recurring revenue $3.7M (+15% YoY); record consumable revenue.
- Placed three Growth Direct systems; reaffirms FY2024 revenue guidance of at least $27M.
- Cash, equivalents and investments $79.5M; no debt; runway into H2 2026.
- Growth Direct Rapid Sterility platform on track for mid-2024 launch.

## SEC filing metadata
- accession: 0001380106-24-000125
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000125/0001380106-24-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000125/rpid-20240503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-24-000125
- JSON: https://secwatch.observer/filing/0001380106-24-000125.json
- Plain text: https://secwatch.observer/filing/0001380106-24-000125.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported first quarter ended March 31, 2024 results: revenue $5.6 million, net income $13.3 million, EPS $0.31. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $5.6 million
  - Net income: $13.3 million
  - EPS: $0.31
  - Guidance: reaffirmed
  - Result: reported results
  source text: Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010624000125/0001380106-24-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.